Authors’ Reply to Mazza et al.: “Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence”

Eric J. Lenze; Angela M. Reiersen; Shelley N. Facente

doi:10.1007/s40265-022-01681-8

Authors’ Reply to Mazza et al. “Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence”

Eric J. Lenze
, Angela M. Reiersen
, Shelley N. Facente

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	353-354
Number of pages	2
Journal	Drugs
Volume	82
Issue number	3
DOIs	https://doi.org/10.1007/s40265-022-01681-8
State	Published - Feb 2022

Access to Document

10.1007/s40265-022-01681-8

Cite this

@article{51305dc6c32d4ecb99d3da95653cd1a2,

title = "Authors{\textquoteright} Reply to Mazza et al.: “Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence”",

author = "Lenze, \{Eric J.\} and Reiersen, \{Angela M.\} and Facente, \{Shelley N.\}",

note = "Funding Information: The original article this letter relates to was supported in part by a gift to the Keck School of Medicine of the University of Southern California by the W.M. Keck Foundation. ",

year = "2022",

month = feb,

doi = "10.1007/s40265-022-01681-8",

language = "English",

volume = "82",

pages = "353--354",

journal = "Drugs",

issn = "0012-6667",

number = "3",

}

TY - JOUR

T1 - Authors’ Reply to Mazza et al.

T2 - “Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence”

AU - Lenze, Eric J.

AU - Reiersen, Angela M.

AU - Facente, Shelley N.

N1 - Funding Information: The original article this letter relates to was supported in part by a gift to the Keck School of Medicine of the University of Southern California by the W.M. Keck Foundation.

PY - 2022/2

Y1 - 2022/2

UR - https://www.scopus.com/pages/publications/85124399632

U2 - 10.1007/s40265-022-01681-8

DO - 10.1007/s40265-022-01681-8

M3 - Letter

C2 - 35150436

AN - SCOPUS:85124399632

SN - 0012-6667

VL - 82

SP - 353

EP - 354

JO - Drugs

JF - Drugs

IS - 3

ER -

Authors’ Reply to Mazza et al. “Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence”

Access to Document

Other files and links

Cite this